Literature DB >> 7849006

Structural basis for pleckstrin homology domain mutations in X-linked agammaglobulinemia.

M Vihinen1, M J Zvelebil, Q Zhu, R A Brooimans, H D Ochs, B J Zegers, L Nilsson, M D Waterfield, C I Smith.   

Abstract

Deficiencies in a tyrosine kinase, designated Btk, cause X-linked agammaglobulinemia (XLA) in man, a hereditary defect of B-cell differentiation. Mutations in the newly found PH domain located at the N-terminus of Btk have been shown to be the direct cause of XLA, and here two new mutations, T33P and V64F, are presented. Btk is thus far the only protein in which mutations of the PH domain have been found to cause a disease. The three-dimensional structure of the Btk PH domain was modeled on the basis of the dynamin PH structure. Despite a relatively low sequence similarity the Btk PH domain seems to have the same two beta-sheet structure observed in the known structures. The model was used to interpret the structural basis for disease in five independent point mutations and in an insertion in patients with XLA. The mutated residues F25, V64, and V113, and possibly residue(s) around Q103, could form a binding site, since these amino acids are located close to each other on the surface of the molecule.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7849006     DOI: 10.1021/bi00005a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  The role of the PH domain in the signal-dependent membrane targeting of Sos.

Authors:  R H Chen; S Corbalan-Garcia; D Bar-Sagi
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

Review 2.  X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase.

Authors:  C I Smith; C M Bäckesjö; A Berglöf; L J Brandén; T Islam; P T Mattsson; A J Mohamed; S Müller; B Nore; M Vihinen
Journal:  Springer Semin Immunopathol       Date:  1998

3.  BTKbase, mutation database for X-linked agammaglobulinemia (XLA)

Authors:  M Vihinen; B H Belohradsky; R N Haire; E Holinski-Feder; S P Kwan; I Lappalainen; H Lehväslaiho; T Lester; A Meindl; H D Ochs; J Ollila; I Vorechovsky; M Weiss; C I Smith
Journal:  Nucleic Acids Res       Date:  1997-01-01       Impact factor: 16.971

4.  Specific role for the PH domain of dynamin-1 in the regulation of rapid endocytosis in adrenal chromaffin cells.

Authors:  C R Artalejo; M A Lemmon; J Schlessinger; H C Palfrey
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

5.  Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia.

Authors:  S R Tzeng; M T Pai; F D Lung; C W Wu; P P Roller; B Lei; C J Wei; S C Tu; S H Chen; W J Soong; J W Cheng
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

6.  Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia.

Authors:  R A Brooimans; A J van den Berg; G T Rijkers; L A Sanders; J K van Amstel; M G Tilanus; M J Grubben; B J Zegers
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

7.  Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia.

Authors:  M Hyvönen; M Saraste
Journal:  EMBO J       Date:  1997-06-16       Impact factor: 11.598

8.  N terminus of Sos1 Ras exchange factor: critical roles for the Dbl and pleckstrin homology domains.

Authors:  X Qian; W C Vass; A G Papageorge; P H Anborgh; D R Lowy
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

9.  PTB domain of insulin receptor substrate-1 binds inositol compounds.

Authors:  H Takeuchi; M Matsuda; T Yamamoto; T Kanematsu; U Kikkawa; H Yagisawa; Y Watanabe; M Hirata
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

10.  BTKbase, mutation database for X-linked agammaglobulinemia (XLA).

Authors:  M Vihinen; T Iwata; C Kinnon; S P Kwan; H D Ochs; I Vorechovský; C I Smith
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.